Forendo Pharma

Aug 20, 2019

Forendo Pharma Commences Phase 1b Proof of Mechanism Study with its Lead Endometriosis Program, HSD17B1 Inhibitor FOR-6219

Jul 19, 2019

Sunstone Life Science Ventures Joins Forendo Pharma Investor Syndicate

Mar 07, 2019

Forendo Pharma Successfully Completes Phase 1a Clinical Trial of FOR-6219 for the Treatment of Endometriosis

Sep 05, 2018

Vesalius Biocapital III Partners Joins Forendo Pharma Investor Syndicate

Jul 04, 2018

Forendo Pharma Initiates Phase I Study for Potential New, Targeted Treatment for Endometriosis

Mar 19, 2018

Forendo Pharma Receives EUR3 Million Loan from Business Finland to Develop Novel Treatments for Endometriosis

Mar 07, 2018

David Colpman Joins the Board of Directors of Forendo Pharma

Oct 10, 2017

Forendo Pharma Nominates World Class Scientific Advisory Board and Elects Professor Linda Giudice as the Chairperson